Arbaclofen
- Generic Name
- Arbaclofen
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClNO2
- CAS Number
- 69308-37-8
- Unique Ingredient Identifier
- NYU6UTW25B
- Background
Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as a treatment for spasticity due to multi...
- Indication
Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 442
- Registration Number
- NCT05179577
Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Clinical Research Associates, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT04271332
- Locations
- 🇺🇸
New York State Psychiatric Institute (NYSPI), New York, New York, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Evdokia Anagnostou
- Target Recruit Count
- 90
- Registration Number
- NCT03887676
- Locations
- 🇨🇦
McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada
🇨🇦Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
🇨🇦Queen's Universtiy, Kingston, Ontario, Canada
Arbaclofen in Children and Adolescents With ASD
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Celso Arango, MD, PhD
- Target Recruit Count
- 124
- Registration Number
- NCT03682978
- Locations
- 🇬🇧
King's College London, London, United Kingdom
🇫🇷Robert Debré Hospital, Paris, France
🇪🇸Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, SERMAS, Madrid, Spain
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT03319732
- Locations
- 🇺🇸
Neuro Pain Medical Center, Fresno, California, United States
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 536
- Registration Number
- NCT03290131
- Locations
- 🇵🇱
Neuro-Medic, Katowice, Poland
🇵🇱"MEDYK" Stanislaw Mazur Sp. z o.o. (LLC) Medical Centre, Rzeszów, Poland
🇵🇱Neurology Center Krzysztof Selmaj, Łódź, Poland
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01844232
- Locations
- 🇷🇺
Osmotica Study Site-555, Tonnel'nyy, Russian Federation
🇺🇸Osmotica Study Site-161, Plainview, New York, United States
🇺🇸Osmotica Study Site-155, Raleigh, North Carolina, United States
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- RVL Pharmaceuticals, Inc.
- Target Recruit Count
- 353
- Registration Number
- NCT01743651
- Locations
- 🇺🇸
Osmotica Study Site-127, Pittsburgh, Pennsylvania, United States
🇺🇸Osmotica Study Site-129, Seattle, Washington, United States
🇺🇸Osmotica Study Site-131, Cincinnati, Ohio, United States
An Open Label Extension Study in Subjects With Fragile X Syndrome
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT01555333
- Locations
- 🇺🇸
Seaside Therapeutics Site #20, Decatur, Georgia, United States
🇺🇸Seaside Therapeutics Site #05, Akron, Ohio, United States
🇺🇸Seaside Therapeutics Site #12, Baltimore, Maryland, United States
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT01325220
- Locations
- 🇺🇸
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University of Massachusetts, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.